ReviewInternational ophthalmology2024
Fuchs endothelial corneal dystrophy: an updated review.
Review in International ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 28 citations in OpenAlex.
- Repeat surgical interventions in non-Fuchs corneal dystrophies: insights from eight decades of histopathological and clinical data.Eye (London, England) · 2026Article
- Modern Diagnostic Modalities for Fuchs' Endothelial Corneal Dystrophy: A Comparative Analysis Using Scheimpflug Tomography.Medicina (Kaunas, Lithuania) · 2026Article
- Regenerative effects of RKI-1447 on human corneal endothelial cells: a comparative study.BMC ophthalmology · 2026Article
- Iridocorneal endothelial syndrome manifesting 4.5 years after toric implantable collamer lens implantation: a case report.BMC ophthalmology · 2026Article
- Corneal Remodeling After DMEK in Fuchs Endothelial Dystrophy Patients: Quantitative and Qualitative Changes.Life (Basel, Switzerland) · 2026Article
- Validation of Automated Software for Guttae Quantification in Fuchs Endothelial Corneal Dystrophy.Translational vision science & technology · 2026Article
- PEDF Prevents Corneal Endothelial Dysfunction of Fuchs Endothelial Corneal Dystrophy.Investigative ophthalmology & visual science · 2026Article
- Deferoxamine Modulates Corneal Endothelial Cell Biological Properties Associated with Increased VEGF Expression.Medicina (Kaunas, Lithuania) · 2026Article
- Antioxidant Capacity in Fuchs' Dystrophy and Its Relationship with Cataract: A Pilot Study.Journal of clinical medicine · 2026Article
- Predictive biomarkers for the prognosis of phacoemulsification and posterior chamber intraocular lens implantation in Fuchs endothelial corneal dystrophy.BMC ophthalmology · 2025Article
- Molecular Studies ofInternational journal of molecular sciences · 2025Article
- Bioengineering Strategies for Corneal Endothelial Cell Injection Therapy: Advances, Challenges, and Clinical Translation.Bioengineering (Basel, Switzerland) · 2025Review
- Enabling In Vivo Longitudinal Evaluation of Descemet's Membrane Thickness in Wild-type and FECD Mice Using Self-Referenced Optical Coherence Microscopy.Investigative ophthalmology & visual science · 2025Article
- Validation of the Italian Version of the Visual Function and Corneal Health Status (V-FUCHS) Questionnaire: A Patient-Reported Visual Disability Instrument for Fuchs' Endothelial Corneal Dystrophy.Journal of clinical medicine · 2025Article
- Comprehensive analysis of splicing variants in corneal endothelial cells of patients with Fuchs endothelial corneal dystrophy.Scientific reports · 2025Article
- From Genes to Disease: ReassessingInternational journal of molecular sciences · 2025Article
- Prevalence and morphometric characteristics of primary cornea guttata in a Hispanic population.International ophthalmology · 2025Article
- How "Omics" Studies Contribute to a Better Understanding of Fuchs' Endothelial Corneal Dystrophy.Current issues in molecular biology · 2025Review
- Ten-year outcomes after DMEK, DSAEK, and PK: insights on graft survival, endothelial cell density loss, rejection and visual acuity.Scientific reports · 2025Article
- In vivo Confocal Microscopy for Corneal and Ocular Surface Pathologies: A Comprehensive Review.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present review will summarize FECD-associated genes and pathophysiology, diagnosis, current therapeutic approaches, and future treatment perspectives.
methodsLiterature review.
resultsFuchs' endothelial corneal dystrophy (FECD) is the most common bilateral corneal dystrophy and accounts for one-third of all corneal transplants performed in the US. FECD is caused by a combination of genetic and non-heritable factors, and there are two types: early-onset FECD, which affects individuals from an early age and is usually more severe, and late-onset FECD, which is more common and typically manifests around the age of 40. The hallmark findings of FECD include progressive loss of corneal endothelial cells and the formation of focal excrescences (guttae) on the Descemet membrane. These pathophysiological changes result in progressive endothelial dysfunction, leading to a decrease in visual acuity and blindness in later stages. The present review will summarize FECD-associated genes and pathophysiology, diagnosis, current therapeutic approaches, and future treatment perspectives.
conclusionWith the characterization and understanding of FECD-related genes and ongoing research into regenerative therapies for corneal endothelium, we can hope to see more significant improvements in the future in the management and care of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.